Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV-1 Protease Inhibitor
Lasinavir (CGP 61755) is a selective inhibitor of HIV-1 protease, exhibiting an IC50 value of 1 nM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for studying HIV-1 infection and pathogenesis. Lasinavir is applicable in research focused on antiretroviral therapies and the mechanism of protease inhibition in viral replication. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
Chitinase Inhibitor
Argifin is a potent chitinase inhibitor that demonstrates sub-nanomolar activity, targeting multiple chitinase enzymes. It exhibits impressive IC50 values of 0.025 μM for SmChiA from Serratia marcescens, 6.4 μM for SmChiB, 1.1 μM for Aspergillus fumigatus chitinase B1, and 4.5 μM for human chitotriosidase. Argifin is instrumental in studies exploring chitin metabolism and offers potential applications in antifungal research and elucidation of chitinase-related diseases. -
Antiplasmodial Agent
19,20-Epoxycytochalasin D is a cytochalasin derived from the fungal species Nemania sp. It exhibits significant in vitro antiplasmodial activity, making it a valuable compound for malaria research. Additionally, it demonstrates phytotoxic properties, indicating its potential use in studies related to plant biology and herbicide development. -
SDH Inhibitor
Succinate dehydrogenase-IN-2 is a potent inhibitor targeting succinate dehydrogenase (SDH) with an IC50 value of 1.22 mg/L. This compound demonstrates significant antifungal activity, effectively inhibiting a range of fungal pathogens including S. sclerotiorum, V. mali, G. graminis, R. solani, and B. cinerea, with EC50 values in the range of 0.52-3.42 mg/L. It is a valuable tool for research applications focusing on fungal infections and metabolic pathways involving SDH. -
HIV-1 Capsid Inhibitor
Lenacapavir is an HIV-1 capsid inhibitor that targets the interface between capsid hexamers and CA monomers, disrupting capsid assembly and viral maturation. This compound inhibits the nuclear translocation of HIV-1 DNA and interferes with CA-mediated protein-protein interactions, resulting in reduced formation of 2-LTR circles and pre-integration proviruses. Additionally, Lenacapavir induces aberrant capsids and decreases the production of mature HIV-1. It demonstrates efficacy against various HIV-1 subtypes and clinical isolates, making it a valuable reagent for research on HIV-1 infection. -
HIV-1 RT Inhibitor
Tenofovir diphosphate disodium is a potent inhibitor of HIV-1 reverse transcriptase, with a Ki value of 1.55 μM for DNA and 0.022 μM for RNA. This compound exhibits key biological activity as an antiretroviral agent, making it a valuable tool for the study of HIV and AIDS. It is suitable for research applications focused on understanding viral replication and developing therapeutic strategies against HIV infection. -
HIV-1 TAT Peptide
TAT (YGRKKRRQRRR) is a cell-penetrating peptide derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1). It enhances the solubility and yield of heterologous proteins, making it a valuable tool in research applications related to protein expression and purification. TAT's ability to facilitate cellular uptake has made it a useful reagent in studies exploring intracellular delivery mechanisms and molecular therapeutics. -
HIV-1 Inhibitor
PYR01 is a non-nucleoside reverse transcriptase inhibitor that targets HIV-1 by activating the death of infected cells. It exhibits significant antiviral activity, demonstrating IC50 values of 27.5 nM and 39.7 nM for cytotoxic and antiviral effects, respectively. By promoting HIV-1 Gag-Pol dimerization and intracellular activation of HIV-1 protease, PYR01 induces selective cytotoxicity in HIV-1-infected cells. This compound is valuable for research focused on HIV biology and therapeutic strategies. -
HIV-1 Inhibitor
PF-3450074 is a specific inhibitor of the HIV-1 capsid protein (CA), exhibiting broad-spectrum antiviral activity against various HIV isolates with submicromolar potency (EC50=8-640 nM). This compound functions at an early stage of the HIV-1 life cycle, impeding viral replication by competing with the binding of nuclear host factors CPSF6 and NUP153. Additionally, PF-3450074 disrupts key processes such as uncoating, assembly, and reverse transcription, making it a valuable tool for HIV research. -
CD4-Targeted HIV Inhibitor
Cyclotriazadisulfonamide (CADA) is a selective inhibitor of HIV entry that targets CD4. It functions by inhibiting the co-translational translocation of human CD4 into the endoplasmic reticulum lumen in a signal peptide-dependent manner. In addition, CADA acts as a Sec61 translocon inhibitor, making it a valuable tool for studying HIV pathogenesis and potential therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
Glycolithocholic acid 3-sulfate is a cholic acid derivative that serves as an effective HIV-1 inhibitor. It demonstrates the ability to inhibit the replication of HIV-1 in vitro, making it a valuable tool for studying HIV infection. Additionally, Glycolithocholic acid 3-sulfate may have relevance in research related to gallbladder disease. -
V-ATPase/HIV-1 Inhibitor
Diphyllin is a potent inhibitor of vacuolar H+-ATPase (V-ATPase) with an IC50 of 17 nM, and also acts as an HIV-1 inhibitor with an IC50 of 0.38 μM. This compound effectively disrupts the acidification of osteoclast lysosomes, leading to significant inhibition of osteoclast-mediated bone resorption while leaving osteoblastic bone formation unaffected. Diphyllin is valuable for investigating bone metabolism-related diseases and exploring therapeutic avenues for conditions characterized by excessive bone resorption. -
HIV Inhibitor
Censavudine is a nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. With EC50 values ranging from 30 nM to 81 nM for HIV-2 and 450 nM to 890 nM for HIV-1, this compound is effective in disrupting viral replication. Additionally, Censavudine possesses a reactive alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a versatile tool for click chemistry applications in drug development and molecular biology research. -
HIV gag mRNA Antagonist
Trecovirsen is an antiviral agent that targets HIV gag mRNA by hybridizing with its complementary sequence at the initiation site. This interaction leads to the induction of a reversible, dose-dependent prolongation of activated partial thromboplastin time due to its polyanionic properties. Trecovirsen is applicable for research on HIV infection, providing insights into the mechanisms of viral replication and potential therapeutic strategies. -
HIV/NRTTI Inhibitor
MK-8527 is an orally active inhibitor of HIV that functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). This compound exhibits antiviral activity by impeding reverse transcriptase, an essential enzyme for viral replication. MK-8527 is primarily utilized in research focused on the development of HIV therapeutic strategies and studying mechanisms of resistance in retroviral infections. -
HIV Inhibitor
2',3'-Dideoxyadenosine is an inhibitor of HIV replication that functions by incorporating into viral DNA, thereby terminating chain elongation. This compound exhibits significant antiretroviral activity and is utilized in research to understand mechanisms of HIV infection and the development of therapeutic strategies against the virus. Its efficacy makes it a valuable tool in antiviral studies and drug development pipelines focused on HIV. -
HIV-1 Polypeptide
HIV-1 TAT (48-60) is a cell-penetrating peptide derived from residues 48-60 of the HIV-1 Tat protein, functioning as a facilitator for cellular uptake. This peptide enables the effective delivery of exogenous macromolecules into cells without causing disruption to cellular integrity. Its unique mechanism enhances research applications in drug delivery, gene therapy, and the study of intracellular processes associated with HIV-1. -
HIV Inhibitor
Zingibroside R1 is a dammarane-type triterpenoid saponin that targets HIV through its inhibitory effects. Isolated from the rhizomes, taproots, and lateral roots of Panax japonicus C. A. Meyer, it demonstrates anti-HIV-1 activity, in addition to notable anti-tumor and anti-angiogenic properties. Zingibroside R1 also inhibits 2-deoxy-D-glucose (2-DG) uptake in EAT cells with an IC50 of 91.3 μM, highlighting its potential for further research in cancer and viral therapies. -
HIV Inhibitor
(R)-Edelfosine, also known as (R)-ET-18-OCH3, is an ether lipid analog that primarily targets HIV through its antiviral properties. This compound exhibits significant anti-HIV activity and demonstrates potential antineoplastic effects. It is commonly utilized in research applications related to antiviral therapies and cancer treatment investigations. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
HIV-1 Integrase Inhibitor
Bictegravir sodium is a highly potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 7.5 nM. This compound exhibits robust and selective anti-HIV activity while maintaining low cytotoxicity. Bictegravir sodium is primarily utilized in research focused on HIV treatment strategies and the development of antiretroviral therapies. -
HIV-1 Integrase Inhibitor
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide is a potent inhibitor of HIV-1 integrase, targeting both the 3'-processing and strand transfer stages of the integration process. This compound serves as a valuable tool in HIV-1 research, facilitating the study of viral replication and integration mechanisms. Its effectiveness in inhibiting key steps in the integration pathway makes it an important reagent for investigations related to HIV-1 therapeutic development. -
HIV-1 Inhibitor
BIT-225 is an HIV-1 inhibitor that specifically targets the Vpu protein by blocking its ion channel function. This mechanism effectively inhibits the release of HIV-1, particularly in monocyte-derived macrophages, with an EC50 of 2.25 μM. BIT-225 demonstrates a favorable safety profile, exhibiting minimal cytotoxicity (TC50 of 284 μM). This compound is valuable for research into therapeutic strategies for HIV-1. -
HIV Inhibitor
APOBEC3G-IN-1 is a potent inhibitor of the HIV virus that targets the APOBEC3G enzyme. This compound demonstrates significant activity in inhibiting viral replication, making it a valuable tool in HIV research. Its ability to modulate the immune response against HIV provides insights into viral pathogenesis and potential therapeutic strategies. -
HIV-1 Polypeptide
TAT (48-57) is a cell-permeable peptide derived from the HIV-1 transactivator of transcription (Tat) protein, specifically residues 48 to 57. This peptide facilitates the study of viral gene expression and replication by interacting with intracellular targets to enhance the transcriptional activity of HIV-1. TAT (48-57) is utilized in research applications focused on HIV pathogenesis, viral life cycle analysis, and the development of antiviral strategies. -
Anti-HIV Agent
Tucaresol is an orally bioavailable immunopotentiator that enhances T-helper cell activity, evidenced by increased levels of IL-2 and IFN-γ in both mice and humans. This compound exhibits anti-HIV properties, making it a valuable tool in the research of HIV infections and potential treatments. Its ability to modulate immune responses positions Tucaresol as a significant candidate for studies focused on immunological interventions in viral infections. -
HIV-1 Nucleocapsid Protein Inhibitor
Claficapavir is a potent inhibitor of the HIV-1 nucleocapsid protein, specifically designed to interfere with its chaperone functions. With an IC50 of approximately 1 μM and a strong binding affinity (Kd = 20 nM), Claficapavir exhibits significant antiviral activity against HIV-1. This compound serves as a valuable tool for research focused on HIV pathogenesis and therapeutic interventions targeting viral replication. -
HIV-1 inhibitor
HIV-1 inhibitor-6 is a diheteroarylamide-based compound that functions as a potent inhibitor of HIV-1 pre-mRNA alternative splicing. This compound effectively blocks HIV replication and exhibits activity against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. Additionally, HIV-1 inhibitor-6 demonstrates inhibitory effects against various HIV strains that are resistant to existing therapies targeting reverse transcriptase, protease, integrase, and CCR5, with EC50s ranging from 0.9 to 1.5 μM. This compound is a valuable tool for researching HIV-1 mechanisms and therapeutic strategies. -
HIV Inhibitor
Decanoyl-RVKR-CMK TFA is a potent inhibitor of HIV-1, specifically targeting the over-expression of the gp160 protein, thereby blocking its processing. This compound demonstrates significant antiviral activity against HIV-1 replication, making it a valuable tool in the study of HIV biology and therapeutic development. Its application includes research focused on the mechanisms of HIV infection and potential therapeutic interventions. -
HIV Inhibitor
Schisantherin D is a dibenzocyclooctadiene lignan that exhibits significant anti-HIV activity with an EC50 of 0.5 μg/mL. This compound selectively inhibits endothelin receptor B (ETBR) and demonstrates hepatoprotective properties. Schisantherin D is valuable for research applications focused on HIV replication and the exploration of liver protective mechanisms. -
HIV/SARS-CoV Inhibitor
2-Hydroxyacetophenone is an inhibitor targeting HIV and SARS-CoV. This compound exhibits significant antiviral activity, making it a valuable tool for research in the development of therapeutic strategies against these viral infections. Additionally, it serves as a versatile building block for synthesis in various chemical applications. -
HIV-1 Inhibitor
Fipravirimat dihydrochloride is a potent inhibitor of HIV-1, demonstrating significant antiviral activity against this virus. This compound is valuable for research applications focused on HIV and AIDS, facilitating studies aimed at understanding viral replication mechanisms and testing therapeutic strategies. Its efficacy makes it a crucial tool for the development of new antiviral treatments. -
HIV Inhibitor
GSK2838232 is an inhibitor of HIV reverse transcriptase, displaying potent activity against a diverse array of HIV-1 isolates. This compound is crucial for studying HIV replication and has applications in antiviral drug development and research focused on HIV resistance mechanisms. Its effectiveness in inhibiting viral replication makes it a valuable tool for understanding the dynamics of HIV infections and testing therapeutic strategies. -
HIV-1 Inhibitor
Ingenol-3-palmitate is an ingenane diterpenoid that functions as a potent inhibitor of HIV-1, demonstrating an IC50 value of 4.1 nM. This compound, derived from the roots of Euphorbia ebracteolata, exhibits significant antiviral activity, making it a valuable tool in HIV research. Its mechanism of action can enhance understanding of viral replication and potential therapeutic strategies against HIV infection. -
HIV Inhibitor
Gomisin M2, a lignan derived from the fruits of Schisandra rubriflora, serves as an effective HIV inhibitor with an EC50 of 2.4 μM. In addition to its anti-HIV properties, Gomisin M2 demonstrates anti-cancer and anti-allergic activities, indicating its multifaceted biological potential. This compound may also offer valuable insights for research related to Alzheimer’s disease. -
HIV Inhibitor
Azulene, a bicyclic hydrocarbon, exhibits potent anti-HIV activity by targeting viral replication mechanisms. Isolated from chamomile oil, it serves as an important scaffold in medicinal chemistry, facilitating the design of new antiviral agents. Its unique structure and biological properties make it a valuable compound in HIV research and therapeutic development. -
Anti-HIV Agent
Gomisin M1 is a potent anti-HIV agent that acts by inhibiting viral replication. With an EC50 value of less than 0.65 μM, it demonstrates significant efficacy in reducing HIV-1 activity. Its anti-viral properties make it a valuable drug candidate for research in HIV treatment and prevention strategies. -
HIV-1 Inhibitor
BDM-2 is a potent allosteric inhibitor of HIV-1 integrase, specifically targeting the IN-LEDGF interaction. With an IC50 of 47 nM, it exhibits significant anti-retroviral activity and an AC50 for IN multimerization activation of 20 nM. BDM-2 effectively disrupts the binding between the integrase catalytic core domain and the LEDGF/p75 integrase binding domain, with an IC50 of 0.15 μM. This compound demonstrates a high degree of selectivity and a favorable cytotoxicity profile, making it a valuable tool for HIV research. -
HIV-1 Capsid Inhibitor
Lenacapavir sodium is an HIV-1 capsid inhibitor that targets the interaction between capsid hexamers and CA monomers. By disrupting capsid assembly and viral maturation, it inhibits the nuclear translocation of HIV-1 DNA and interferes with CA-mediated protein-protein interactions. Additionally, Lenacapavir sodium reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and diminishes the production of mature HIV-1. This reagent is vital for research focused on HIV-1 infection and explores its effects on various HIV-1 subtypes and clinical isolates. -
HIV Inhibitor
Bz-RS-iSer(3-Ph)-OMe is a potent HIV inhibitor that specifically targets viral replication processes. This compound effectively disrupts the replication cycle of HSV with minimal cytotoxicity and inhibits mitotic divisions in Vero cells. Additionally, Bz-RS-iSer(3-Ph)-OMe influences tumor size in M-MSV models and modulates immune responses by inhibiting PHA-induced T lymphocyte proliferation, making it a valuable tool for research in virology and cancer biology. -
HIV-1 RNase H Inhibitor
HIV-1 inhibitor-45 is a potent inhibitor of the HIV-1 RNase H enzyme, demonstrating an IC50 value of 0.067 μM. This compound exhibits significant antiviral activity against HIV-1, making it a valuable tool for studying viral replication and pathogenesis. However, it is characterized by low cell permeability, with an apparent permeability coefficient (Papp) of less than 0.48 × 10−6 cm/s, which may impact its effectiveness in cellular models. -
HIV-1 Reverse Transcriptase Inhibitor/μ-opioid Receptor Agonist
Corydine targets HIV-1 reverse transcriptase and the μ-opioid receptor, acting as an inhibitor with an IC50 of 356.7 μg/mL against the enzyme and an EC50 of 0.51 μM at the receptor. It exhibits antinociceptive effects through the modulation of MOR, effectively reducing acetic acid-induced writhing behavior. Corydine has also demonstrated the ability to inhibit the proliferation of various cancer cells and immune cells, making it a valuable reagent for research into HIV infection, visceral pain, and various cancers including leukemia, melanoma, bladder cancer, and colon adenocarcinoma. -
HIV-1 Capsid Protein Inhibitor
I-XW-053 is a specific inhibitor of the HIV-1 capsid protein, demonstrating antiviral activity by disrupting the interaction at the N-terminal domain interface (NTD-NTD) of the capsid protein. It effectively suppresses the replication of HIV-189BZ167 with an IC50 value of 164.2 μM. This compound serves as a valuable tool for researchers investigating HIV-1 pathogenesis and potential therapeutic approaches targeting viral replication. -
HIV-1 Nef Binder, IKZF1 Modulator
FC-14369 is a PROTAC degrader that selectively targets the HIV-1 Nef protein, exhibiting a DC50 value of 160 nM. By engaging both Nef and the Cereblon E3 ubiquitin ligase, FC-14369 facilitates the ubiquitination and subsequent proteasomal degradation of Nef, leading to the restoration of CD4 and MHC-I expression on the cell surface and effectively inhibiting HIV-1 replication. This compound is valuable for research focused on HIV infection and AIDS, advancing understanding of therapeutic strategies in viral infections. -
HIV protease Inhibitor
Telinavir is a potent and selective inhibitor of HIV protease. It effectively inhibits various strains of HIV-1, HIV-2, and simian immunodeficiency virus at EC50 values of 26 ng/mL (43 nM). With a high degree of protein binding in human plasma and minimal partitioning into erythrocytes, Telinavir serves as a valuable tool in HIV research and therapeutic development. -
Topo IIKHIV Inhibitor
2,4-Dihydroxypyridine is an effective inhibitor of Topoisomerase IIK HIV, demonstrating a pIC50 of 5.05 against this target. Additionally, it displays antiviral activity against HIV-1 replication with a pIC50 of 4.07. This compound is useful for research into HIV treatment strategies and topoisomerase mechanisms. -
HIV-1 Inhibitor
Fipravirimat is a potent inhibitor of HIV-1 replication, targeting the viral protein's function. It exhibits significant antiviral activity, showing efficacy in blocking viral entry and replication. This compound is applicable for research focused on HIV and AIDS, providing valuable insights into therapeutic strategies against these infections. -
HIV-1 Inhibitor
NBD-14270 is a potent HIV-1 entry antagonist that specifically targets the gp120 protein of the virus. With an IC50 of 180 nM, it exhibits significant antiviral activity against various HIV-1 Env-pseudotyped virus strains. Additionally, NBD-14270 demonstrates low cytotoxicity, with a CC50 exceeding 100 μM, making it a valuable candidate for research applications in HIV-1 inhibition.
